The Scripps Research Institute

University of California

California Institute of Technology

Takeda Pharmaceutical Company Limited

Takeda San Diego, Inc.

Ligand Pharmaceuticals, Inc.

Takeda California, Inc.

Yan Liu

Peter G Schultz

Feng Wang

Sheldon Cao

Jeffrey Alan Stafford

Ying Wang

Yong Zhang

Lin Zhi

Qing Dong

Travis Young

Andre A Kiryanov

Guangsen Fu

Stephen W Kaldor

Donald Karanewsky

Lihong V Wang

Zhe Nie

Stephen L Gwaltney

Jason W Brown

Matthew S Tremblay

Juanjuan Du

Nicole Alvarez

Benjamin Jones

Robert Higuchi

Betty Lam

Nicholas Scorah

Haowen Ruan

Edcon Chang

Srinivasa Reddy Natala

Beverly Lynn Wolgast

Yuecheng Shen

David J Hosfield

Frank L Brodie

Yasuhisa Kohara

Prasuna Guntupalli

Mark E Adams

Jiayu Liao

Victoria Feher

Takashi Ichikawa

Kathleen Aertgeerts

Xianchang Gong

Yang Song

Srinivasa Ready Natala

Nancy K Brennan

Hidehisa Iwata

Chrisopher McBride

Yongfeng Zhao

Christopher Mcbride

Sheldon X Cao

Bheema R Paraselli

Sanjib Das

Beverly Throop

Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.

Relaxin immunoglobulin fusion proteins and methods of use

Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.

Coiled coil immunoglobulin fusion proteins and compositions thereof

A device for irradiating ocular tissue, including a source of electromagnetic radiation; a beacon scattering the electromagnetic radiation transmitted through an opacity in ocular tissue so as to form scattered electromagnetic radiation; a modulator transmitting output electromagnetic radiation having a field determined from a recording of the scattered electromagnetic radiation transmitted through the opacity, so that the output electromagnetic radiation is transmitted through the opacity to the beacon. The device can be used to treat amblyopia or correct optical aberrations in corneal or lens tissue.

Focusing light through cataractous lenses

Disclosed herein are immunoglobulin fusion proteins comprising an insulin therapeutic peptide and an immunoglobulin region that targets the insulin therapeutic peptide to the liver of an individual in need thereof. Further disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject, for example, diabetes and diabetes related conditions.

Insulin immunoglobulin fusion proteins

The disclosure provides method and composition utilizing fluorescent amino acids and endogenous fluorescent proteins comprising a moiety capable of undergoing FRET. The methods and compositions of the disclosure are useful in analyzing protein structure and function, and screening molecular inhibitors.

High-sensitive fluorescent energy transfer assay using fluoresent amino acids and fluorescent proteins

Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Polo-like kinase inhibitors

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein. 

Imidazopyridine compounds

Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

Hydroxysteroid dehydrogenase inhibitors

This invention relates to compounds that bind to mineralocorticoid receptors and/or modulate activity of mineralocorticoid receptors, and to methods for making and using such compounds. Some embodiments relate to compounds of Formula I: or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein R&#x2014;Rare as defined herein.

Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses

Growing community of inventors

San Diego, CA, United States of America

Yan Liu